GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Affymax (Affymax) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Affymax Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison of Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



Affymax  (OTCPK:AFFY) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Affymax Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Affymax's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010